[Nivolumab (colorectal cancer with dMMR or MSI-H, first line, combination with ipilimumab) – Addendum to Project A25-80]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018014830
German
Original Title: Nivolumab (Kolorektalkarzinom mit dMMR oder MSI-H, Erstlinie, Kombination mit Ipilimumab) - Addendum zum Projekt A25-80
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a25-135.html
Year Published: 2025
URL for published report: https://www.iqwig.de/download/a25-135_nivolumab_addendum-zum-projekt-a25-80_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A25-135
MeSH Terms
  • Colorectal Neoplasms
  • Nivolumab
  • Ipilimumab
  • Antineoplastic Combined Chemotherapy Protocols
  • Antineoplastic Agents, Immunological
Keywords
  • Nivolumab
  • Ipilimumab
  • Colorectal Neoplasms
  • Benefit Assessment
  • NCT04008030
  • NCT02563002
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.